That is a possibility,but I would expect one of the larger better capitalized pharmaceutical companies would be more likely to partner with CTIX. I do not believe Cubist is large enough.
Cubist may be more likely to be Brilacidin's victim than partner.
Time will tell. Hopefully we will know more soon. If the phase 2b study is as positive as we have been led to believe and it is released in a few weeks; I think we could have the expanded BOD, uplisting and licensing agreement by the end of the year. Of course the above is JMHO.
Market Data 
Markets 
AI
